Molybdenum Cofactor Deficiency and Sulfite Metabolism

Molybdenum cofactor deficiency (MoCD) is a group of ultrarare autosomal-recessive disorders in which impaired biosynthesis of the molybdenum cofactor (MoCo) abolishes the activity of all Mo-dependent enzymes, most notably sulfite oxidase. Sulfite oxidase normally catalyses the oxidation of sulfite to sulfate, a key step in the catabolism of sulfur-containing amino acids. In MoCD, toxic accumulation of sulfite and its derivatives such as S-sulfocysteine and thiosulfate disrupts cellular redox homeostasis, mitochondrial energy production and neurotransmitter metabolism. Clinical presentation is dominated by neonatal-onset encephalopathy with intractable seizures, feeding difficulties and progressive neurological impairment. Neuroimaging often reveals basal ganglia abnormalities and cerebral atrophy. MoCD is classified into types A, B and C according to the defective biosynthetic step, and only type A is amenable to replacement therapy with cyclic pyranopterin monophosphate (cPMP). Despite advances in understanding the molecular pathways, effective treatments remain limited for most patients, and early diagnosis is critical to improving outcomes.

Research from Nature Portfolio

Studies of patient fibroblasts deficient in ETHE1 or MOCS1 have revealed profound disturbances in mitochondrial bioenergetics, dynamics and endoplasmic reticulum–mitochondria communication. All cell lines exhibited reduced respiration, ATP depletion, increased mitochondrial mass and elevated superoxide levels, accompanied by markers of endoplasmic reticulum stress and apoptosis. Treatment with the mitochondria-targeted antioxidant JP4-039 reduced superoxide accumulation and improved respiratory chain activity in affected cells. These findings highlight previously unrecognised cellular derangements in MoCo deficiency and suggest that targeted antioxidant therapy may serve as an adjuvant strategy alongside cofactor replacement.

Molybdenum Cofactor Deficiency and Sulfite Metabolism publication trend

The graph below shows the total number of articles in molybdenum cofactor deficiency and sulfite metabolism across all publications each year (not limited to Nature Index journals).

Technical terms

Molybdenum cofactor (MoCo): A pterin-based compound that chelates molybdenum and is essential for the activity of all molybdoenzymes except nitrogenase.

Sulfite oxidase (SOX): A mitochondrial enzyme that detoxifies sulfite by oxidising it to sulfate, the final step in sulfur amino-acid catabolism.

Cyclic pyranopterin monophosphate (cPMP): A synthetic precursor of MoCo used as replacement therapy in type A MoCD to restore Mo-dependent enzyme activity.

S-sulfocysteine: A toxic metabolite that accumulates in MoCD, formed by the reaction of excess sulfite with cysteine and implicated in neuronal damage.

References

1. Myelin Disruption, Neuroinflammation, and Oxidative Stress Induced by Sulfite in the Striatum of Rats Are Mitigated by the pan-PPAR agonist Bezafibrate. Cells (2023).
2. Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies. Journal of Inherited Metabolic Disease (2024).
3. ETHE1 and MOCS1 deficiencies: Disruption of mitochondrial bioenergetics, dynamics, redox homeostasis and endoplasmic reticulum-mitochondria crosstalk in patient fibroblasts. Scientific Reports (2019).
4. Molybdenum cofactor deficiency: A natural history. Journal of Inherited Metabolic Disease (2022).